Boehringer Ingelheim USA Corporation

The precision medicine market, valued at $73.11 billion in 2023, is projected to grow to $118.08 billion by 2028, driven by rising cancer prevalence and strategic collaborations. It segments by technology, application, and end-use, with major players including Roche, Pfizer, and Novartis.

Boehringer Ingelheim reported 7.4% net sales growth in H1 2024, driven by high demand for its medications. The company achieved milestones in CRM health and oncology, with promising Phase II results for survodutide in MASH and Phase Ia/Ib trial data for Zongertinib. Boehringer plans up to 25 new Human Pharma launches by 2030 and 20 in Animal Health by 2026.

Companies are competing in the weight loss drug market, with Zealand Pharma, Viking Therapeutics, Terns Pharmaceuticals, Structure Therapeutics, Altimmune, Pfizer, and Amgen developing new treatments. Eli Lilly and Novo Nordisk lead with drugs like Ozempic and Mounjaro, also working on next-gen drugs. The market could reach $100 billion by 2030, with Lilly and Novo expected to dominate due to first-mover advantage and ongoing research into additional health benefits.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.

Switzerland excels in life sciences due to its strong regional hubs like Basel, Zurich, and Geneva/Lausanne, fostering innovation through bioparks and collaboration between academia and industry. This ecosystem supports start-ups and attracts global talent, maintaining Switzerland's leadership in drug discovery and biotech advancements.

QUANTRO Therapeutics achieved a milestone in its joint R&D with Boehringer Ingelheim, successfully applying QUANTROseq® technology to identify high-quality hits for undruggable transcription factors, aiming to develop first-in-class cancer treatments. The collaboration could exceed EUR 500 million in value, focusing on innovative cancer therapies.

The 9th annual CRAACO® conference, focusing on integrating clinical research with care to enhance trial participation and health outcomes, will be held on September 16, 2024, in Philadelphia. It aims to unite stakeholders to improve access to clinical trials, especially in underserved areas, and discuss the convergence of clinical care and research.

The systemic sclerosis market is projected to grow significantly by 2034, driven by increasing prevalence, patient awareness, and novel therapies. Key companies like Kyowa Hakko Kirin and AstraZeneca are developing treatments such as Brodalumab and CABA-201, which have received regulatory designations. The market dynamics are influenced by emerging therapies, diagnostic improvements, and challenges like treatment eligibility and reimbursement.

DelveInsight's report forecasts an increase in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) cases by 2034, highlighting the UK's highest prevalence. With 83% of 64,000 cases diagnosed in 2023, there's a call for better screening. Females are more affected, and severe cases account for 30%. Emerging therapies like Mycophenolate mofetil and Nintedanib are promising, with companies like Genentech and Boehringer Ingelheim leading the market.

QUANTRO Therapeutics, in collaboration with Boehringer Ingelheim, achieved a milestone using QUANTROseq® technology, successfully identifying high-quality hits for an undruggable transcription factor, aiming to develop first-in-class cancer treatments to address unmet patient needs.